why RHT should be a $1.00 now, page-24

Agree revenue growth is a key driver to seeing an appreciating share price. I may be a bit ambitious here, HepaFat-AI has a total addressable market of 2.3 billion people that live with non-alcholic fatty liver disease, this is growing year on year (as referenced in all the recent announcements).

Even if RHT is to acquire 1% of the addressable target market that is 23 million scans. This will not occur over 1 year, it may take many years to even acquire 1% of the addressable target market - but the numbers are truly amazing.

I don't know the price of what will be charged for the use of the product. But a $25 - $75 per scan swing produces revenue of anywhere from $575m to $1.725b.

All medical companies that have FDA, TGA, CE approvals admit all the $$ cost is at the front end which takes place during development and testing of a product. Therefore, most of the return now we have approved products should have minimal capital expenditure impacts.

Artificial intelligence is a real game change in medical field and RHT is also undertaking more research and analysis into other AI products.

This is just the beginning for this little minnow.